ArticleArchives of toxicology2016
Expert consensus on an in vitro approach to assess pulmonary fibrogenic potential of aerosolized nanomaterials.
Article in Archives of toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 65 citations in OpenAlex.
- Beyond cytotoxicity: pollutant mixtures elicit unconventional epithelial-fibroblast signaling in a human lung air-liquid interface co-culture model.Frontiers in toxicology · 2025Article
- Bridging Smart Nanosystems with Clinically Relevant Models and Advanced Imaging for Precision Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Use of quantitativeFrontiers in toxicology · 2024Article
- Lung Organoids in Smoking Research: Current Advances and Future Promises.Biomolecules · 2022Review
- Dynamic Fluid Flow Exacerbates the (Pro-)Inflammatory Effects of Aerosolised Engineered Nanomaterials In Vitro.Nanomaterials (Basel, Switzerland) · 2022Article
- IVIVE: Facilitating the Use ofToxics · 2022Review
- Experimental and Computational Nanotoxicology-Complementary Approaches for Nanomaterial Hazard Assessment.Nanomaterials (Basel, Switzerland) · 2022Review
- The effects of gene × environment interactions on silver nanoparticle toxicity in the respiratory system: An adverse outcome pathway.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Cytotoxicity analysis of biomass combustion particles in human pulmonary alveolar epithelial cells on an air-liquid interface/dynamic culture platform.Particle and fibre toxicology · 2021Article
- A Complete In Vitro Toxicological Assessment of the Biological Effects of Cerium Oxide Nanoparticles: From Acute Toxicity to Multi-Dose Subchronic Cytotoxicity Study.Nanomaterials (Basel, Switzerland) · 2021Article
- 3D Printer Particle Emissions: Translation to Internal Dose in Adults and Children.Journal of aerosol science · 2021Article
- Long-term evolution of the epithelial cell secretome in preclinical 3D models of the human bronchial epithelium.Scientific reports · 2021Article
- Myeloperoxidase Inhibition Decreases the Expression of Collagen and Metallopeptidase in Mare Endometria under In Vitro Conditions.Animals : an open access journal from MDPI · 2021Article
- Nanotoxicology and Nanosafety: Safety-By-Design and Testing at a Glance.International journal of environmental research and public health · 2020Review
- Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.Particle and fibre toxicology · 2020Review
- Utilizing Organoid and Air-Liquid Interface Models as a Screening Method in the Development of New Host Defense Peptides.Frontiers in cellular and infection microbiology · 2020Review
- Substrate Stiffness-Dependent Carbon Nanotube-Induced Lung Fibrogenesis.Nano letters · 2019Article
- Medium throughput breathing human primary cell alveolus-on-chip model.Scientific reports · 2018Article
- Effects of Sample Preparation on Particle Size Distributions of Different Types of Silica in Suspensions.Nanomaterials (Basel, Switzerland) · 2018Article
- Hazard and risk assessment strategies for nanoparticle exposures: how far have we come in the past 10 years?F1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 14 institutions in 6 countries.
Funding
Abstract
The increasing use of multi-walled carbon nanotubes (MWCNTs) in consumer products and their potential to induce adverse lung effects following inhalation has lead to much interest in better understanding the hazard associated with these nanomaterials (NMs). While the current regulatory requirement for substances of concern, such as MWCNTs, in many jurisdictions is a 90-day rodent inhalation test, the monetary, ethical, and scientific concerns associated with this test led an international expert group to convene in Washington, DC, USA, to discuss alternative approaches to evaluate the inhalation toxicity of MWCNTs. Pulmonary fibrosis was identified as a key adverse outcome linked to MWCNT exposure, and recommendations were made on the design of an in vitro assay that is predictive of the fibrotic potential of MWCNTs. While fibrosis takes weeks or months to develop in vivo, an in vitro test system may more rapidly predict fibrogenic potential by monitoring pro-fibrotic mediators (e.g., cytokines and growth factors). Therefore, the workshop discussions focused on the necessary specifications related to the development and evaluation of such an in vitro system. Recommendations were made for designing a system using lung-relevant cells co-cultured at the air-liquid interface to assess the pro-fibrogenic potential of aerosolized MWCNTs, while considering human-relevant dosimetry and NM life cycle transformations. The workshop discussions provided the fundamental design components of an air-liquid interface in vitro test system that will be subsequently expanded to the development of an alternative testing strategy to predict pulmonary toxicity and to generate data that will enable effective risk assessment of NMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.